Objectives: To highlight the utility of a tangential approach in the fine-needle aspiration (FNA) technique for obtaining cellular material adequate for a conclusive diagnosis in diffusely enlarged breast without a discrete lump. Study Design: FNA was performed on 5 women clinically suspected to have inflammatory breast cancer (IBC). All had unilateral diffusely enlarged breasts with peau d’orange changes of the skin. No distinct lump was palpable. The procedure was performed using a 10 cm3 syringe with a tangential approach of a 23-gauge needle in all 4 quadrants with extra passes in the antigravity areas. Rapid on-site evaluation for adequacy was done. Results: All women were of African descent within the age range of 34–57 years. One case had a recent history of lactation. FNA smears showed low-to-moderate cellularity. One case was suspicious and 4 were positive for ductal carcinoma. Core biopsy confirmed IBC in 3 cases. Two cases had a mastectomy; 1 of these cases had preoperative neoadjuvant chemotherapy. Conclusion: The approach of FNA used in these cases helped to establish the diagnosis of IBC in 4 women presenting with a diffusely enlarged and tender breast, resulting in the timely initiation of appropriate management. The technique needs to be assessed in a larger cohort of women with diffusely enlarged breast to evaluate its diagnostic utility.

Keywords:
Fine-needle aspiration, Inflammatory breast cancer, Cytology, Pitfalls, Mastitis, Diffuse enlargement, Breast, East Africa
1.
Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M: Approach to inflammatory breast cancer. Can Fam Physician 2009;55:25–31.
2.
Singletary SE, Cristofanilli M: Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35:7–10.
3.
Le-Petross CH, Bidaut L, Yang WT: Evolving role of imaging modalities in inflammatory breast cancer. Semin Oncol 2008;35:51–63.
4.
Dodd LG, Layfield LJ: Fine-needle aspiration of inflammatory carcinoma of the breast. Diagn Cytopathol 1996;15:363–366.
5.
Akhtar M: Fine-needle biopsy technique for diagnosis of inflammatory carcinoma of the breast. Diagn Cytopathol 1996;15:76–77.
6.
Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH: Trends in inflammatory breast cancer incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966–975.
7.
Soliman AS, Banerjee M, Lo AC, et al: High proportion of inflammatory breast cancer in the population-based cancer registry of Gharbiah, Egypt. Breast J 2009;15:432–434.
8.
Boussen H, Bouzaiene H, Ben Hassouna J, et al: Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 2008;35:17–24.
9.
Levine PH, Veneroso C: The epidemiology of inflammatory breast cancer. Semin Oncol 2008;35:11–16.
10.
Ferdous CS, Islam TM, Meza LA: Review of inflammatory breast cancer: a meta-analysis. J Clin Oncol 2008;26(suppl):1131.
11.
Fulciniti F, Losito S, Botti G, et al: Metastases to the breast: role of fine-needle cytology samples. Our experience with nine cases in 2 years. Annals of Oncology 2009;19:682–687.
12.
Brouwers B, Paridaens R, Lobelle JP, et al: Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer. Tumour Biol 2008;29:211–216.
13.
Yang WT, Le-Petross HT, Macapinlac H, et al: Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417–426.
14.
Resetkova E: Pathologic aspects of inflammatory breast carcinoma. 1. Histomorphology and differential diagnosis. Semin Oncol 2008;35:25–32.
15.
Ellis IO, Schnitt SJ, Satre-Garau X, et al: Invasive breast carcinoma; in Tavassoli FA, Devilee P (eds): Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC press, 2003, pp 13–59.
16.
Gong Y: Pathologic aspects of inflammatory breast cancer. 2. Biologic insights into its aggressive phenotype. Semin Oncol 2008;35:33–40.
17.
Thapaliya P, Karlin NJ: An update on inflammatory breast cancer. Oncol Rev 2009;3:73–78.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.